In a report issued on May 15, Sean Lavin from BTIG reiterated a Buy rating on Viewray (NASDAQ: VRAY), with a price target of $10. The company’s shares opened today at $6.05.

According to TipRanks.com, Lavin is a 5-star analyst with an average return of 11.4% and a 58.5% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Trivascular Technologies, and Obalon Therapeutics Inc.

Currently, the analyst consensus on Viewray is Strong Buy and the average price target is $9.33, representing a 54.2% upside.

In a report released yesterday, Aegis Capital also reiterated a Buy rating on the stock with a $11 price target.

Based on Viewray’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $1.23 million and GAAP net loss of $27.96 million. In comparison, last year the company earned revenue of $5.46 million and had a GAAP net loss of $13.37 million.

Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ViewRay, Inc. engages in the research, development, and manufacture of magnetic resonance imaging (MRI) system. Its product includes MRIdian, which supports image-guided radiation therapy, stereotactic radiation therapy, and radiosurgery. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH.